Iconic Therapeutics, Inc. is a biopharmaceutical company dedicated to leveraging its deep insight into tissue factor (TF) biology and TF’s role in inflammation, tumor growth, and angiogenesis to develop new therapeutics for retinal and inflammatory diseases, as well as cancer. The Company has developed a portfolio of proprietary molecules which bind to and antagonize TF expressed in several disease states. In December 2020, Iconic licensed to Exelixis its tissue factor-targeting antibody drug conjugate ahead of a planned Investigational New Drug Application filing by Exelixis. Please visit www.iconictherapeutics.com for additional information.